PRESS RELEASE published on 02/10/2026 at 07:30, 8 months 18 days ago Informations privilégiées / Autres communiqués L'Hôpital national des 15-20 et GenSight Biologics traitent le premier patient dans l'étude REVISE de GS010/LUMEVOQ contre la neuropathie optique héréditaire de Leber en France GenSight Biologics Neuropathie Optique GS010/LUMEVOQ Hôpital Des 15-20 Étude REVISE
PRESS RELEASE published on 02/10/2026 at 07:30, 8 months 18 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 9 months ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
BRIEF published on 01/29/2026 at 00:26, 9 months ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 9 months ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 9 months 30 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
BRIEF published on 12/29/2025 at 08:05, 9 months 30 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
PRESS RELEASE published on 12/29/2025 at 08:00, 9 months 30 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 12/29/2025 at 08:00, 9 months 30 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 10 months 6 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
Published on 10/28/2026 at 22:35, 8 hours 8 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 18 hours 13 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 18 hours 13 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 18 hours 13 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 18 hours 13 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/29/2026 at 06:30, 12 minutes ago Redcare Pharmacy delivers strong Q3, with revenue increasing 18% driven by Rx and adjusted EBITDA margin up 1.0pp YoY to 3.4%.
Published on 10/29/2026 at 06:30, 12 minutes ago Ad hoc announcement pursuant to Art. 53 LR News Release
Published on 10/29/2026 at 06:00, 43 minutes ago Avolta delivers accelerating quarterly growth and margin progression in Q3
Published on 10/29/2026 at 00:15, 6 hours 28 minutes ago Infinite Electronics Showcases Engineered Connectivity Solutions at electronica 2026
Published on 10/28/2026 at 21:35, 9 hours 8 minutes ago Food & Beverage Manufacturers Race to Scale AI Beyond the Pilot Stage
Published on 10/28/2026 at 17:56, 12 hours 47 minutes ago OPR - Mise à disposition de l'addendum au rapport d'expertise indépendante
Published on 10/28/2026 at 17:45, 12 hours 58 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 12 hours 58 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
